Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Guerrero-Zotano Á, et al. Among authors: martin m. Clin Cancer Res. 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. Clin Cancer Res. 2023. PMID: 36749874 Free PMC article. Clinical Trial.
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A. Jara Sánchez C, et al. Among authors: martin m. Breast Cancer Res Treat. 2007 Jan;101(2):215-23. doi: 10.1007/s10549-006-9282-0. Epub 2006 Jul 6. Breast Cancer Res Treat. 2007. PMID: 16823507
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E. Martín M, et al. Breast Cancer Res Treat. 2010 Aug;123(1):149-57. doi: 10.1007/s10549-009-0663-z. Breast Cancer Res Treat. 2010. PMID: 20037779 Clinical Trial.
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
Puente J, López-Tarruella S, Ruiz A, Lluch A, Pastor M, Alba E, de la Haba J, Ramos M, Cirera L, Antón A, Llombart A, Plazaola A, Fernández-Aramburo A, Sastre J, Díaz-Rubio E, Martin M. Puente J, et al. Among authors: martin m. Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10. Breast Cancer Res Treat. 2010. PMID: 20063196
Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Márquez A, Vicente D, García-Sáenz JA, Martín M. Alba E, et al. Among authors: martin m. Breast Cancer Res Treat. 2010 Jul;122(1):169-76. doi: 10.1007/s10549-010-0860-9. Epub 2010 Apr 2. Breast Cancer Res Treat. 2010. PMID: 20361253 Free article. Clinical Trial.
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Tabchy A, et al. Among authors: martin m. Clin Cancer Res. 2010 Nov 1;16(21):5351-61. doi: 10.1158/1078-0432.CCR-10-1265. Epub 2010 Sep 9. Clin Cancer Res. 2010. PMID: 20829329 Free PMC article. Clinical Trial.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Martín M, et al. N Engl J Med. 2010 Dec 2;363(23):2200-10. doi: 10.1056/NEJMoa0910320. N Engl J Med. 2010. PMID: 21121833 Free article. Clinical Trial.
12,485 results
You have reached the last available page of results. Please see the User Guide for more information.